DelveInsight

View All

Delveinsight
Orphan drug development strategies

Introduction A disease that has not been adopted by the pharmaceutical industry because it provides little financial incentive for the private sector to make and market new medications to treat or prevent it.  An orphan disease may be a rare disease or a common disease that has been ignored because it is far more pr...

Find More

Delveinsight
“Endometrial Cancer – Pipeline Insights, 2015”- A DelveInsight’s Report

DelveInsight, the leading market research and consulting company has added a new report “Endometrial Cancer - Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients with up to date ...

Find More

Delveinsight
PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 – A DelveInsight Report

DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA).DelveInsight Report, PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 has received great response and feedback from client...

Find More

Delveinsight
Systemic Juvenile Idiopathic Arthritis -Pipeline Insights, 2015

Juvenile idiopathic arthritis (JIA) Juvenile idiopathic arthritis (JIA) affects children who are less than 16 years old, commonly occurs in children from the ages of 7 to 12. The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA....

Find More

Delveinsight
Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015

DelveInsight, the leading market research and consulting company has added new report  Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015 to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients w...

Find More

Cytotoxic T lymphocyte-associated antigen-4 Market Forecast & Analysis

Cancer is one of the pioneer causes of obliteration. Although a lot of therapies are being developed in this area but still there is a high unmet need. Currently companies are getting inclined towards Immunotherapies which are target specific (monoclonal and conjugated antibodies) and effective. One such therapy are...

Find More

DelveInsight’s Oncology based Reports, 2015

DelveInsight, the leading market research and consulting company has added Oncology based Reports to its portfolio. With this launch DelveInsight now has 100+ Oncology based Reports. In addition to this, our research expertise provides our clients with up to date information of market till the date on which order is...

Find More

Delveinsight
DelveInsight launches Indication Active Pharmaceutical Ingredient (API) Reports

DelveInsight expertise over 400+ Indication Active Pharmaceutical Ingredient (API) Reports DelveInsight, leading Market Research and Business Consulting firm has an expertise in providing business solutions to Pharma and biotech companies. DelveInsight has 400+ Indication API reports on wide range of therapeutic ...

Find More

Delveinsight
DelveInsight Hiring Analysts and Associate Analysts

DelveInsight is Hiring!!! Looking for Passionate Candidates Mail your updated Resume to careers@delveinsight.com JOB DESCRIPTION Profile Offered: Analyst (2-4 years Experienced) Education: M. Pharma/M.tech Biotech/MBA Biotech/B.Tech/ Roles and Responsibilities: Excellent editing, verbal and written ...

Find More

Delveinsight
Outbreak of Companies Challenging New Pathways for Treatment of Pulmonary Arterial Hypertension

Drugs with better pharmacodymics and improved treatment algorithm with antiproliferative and anti-inflammatory treatments are needed! Pulmonary arterial hypertension (PAH) is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction and vascular remodeling that i...

Find More